Agmatine Signaling: Odds and Threads

Cardiovascular Drug Reviews

Volumn 22, Issue 1, 2004, Pages 7-16

  Berkels, Reinhard ^a   Taubert, Dirk ^a   Gründemann, Dirk ^a   Schömig, Edgar ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Agmatine; Agmatine metabolism; Antizyme; Imidazoline binding sites; Polyamines

Indexed keywords

AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; ARGININE; ARGININE DECARBOXYLASE; CLONIDINE; IDAZOXAN; IMIDAZOLINE RECEPTOR; METHOXAMINE; MORPHINE; NALOXONE; NITRIC OXIDE SYNTHASE; PEPTIDE HORMONE; PHENYLEPHRINE; POLYAMINE;

AMINO ACID METABOLISM; BACTERIUM; BINDING SITE; CELL PROLIFERATION; DECARBOXYLATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HORMONE RELEASE; HUMAN; HYPERTENSION; MAMMAL; NEUROTRANSMISSION; NONHUMAN; PLANT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

EID: 1642304083     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2004.tb00128.x     Document Type: Review

References (74)

1. Abe K, Abe Y, Saito H. Agmatine suppresses nitric oxide production in microglia. Brain Res 2000;872: 141-148.
2. Aricioglu-Kartal F, Uzbay IT. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci 1997;61:1775-1781.
3. Auguet M, Viossat I, Marin JG, Chabrier PE. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol 1995;69:285-287.
4. Aziz SM, Gillespie MN, Crooks PA, et al. The potential of a novel polyamine transport inhibitor in cancer chemotherapy. J Pharmacol Exp Ther 1996;278:185-192.
5. Babal P, Ruchko M, Olson JW, Gillespie MN. Interactions between agmatine and polyamine uptake pathways in rat pulmonary artery endothelial cells. Gen Pharmacol 2000;34:255-261.
6. Bence AK, Worthen DR, Stables JP, Crooks PA. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacol Biochem Behav 2003;74:771-775.
7. Berdeu D, Puech R, Loubatieres-Mariani MM, Bertrand G. Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed. Eur J Pharmacol 1996;308:301-304.
8. Blantz RC, Satriano J, Gabbai F, Kelly C. Biological effects of arginine metabolites. Acta Physiol Scand 2000;168:21-25.
9. 2-imidazoline ligands. Br J Pharmacol 1998;125:175-185.
10. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984;230:232-236.
11. 2-drenoceptor or μ-opioid receptor mechanisms. Eur J Pharmacol 1997;331:133-138.
12. Cabella C, Gardini G, Corpillo D, et al. Transport and metabolism of agmatine in rat hepatocyte cultures. Eur J Biochem 2001;268:940-947.
13. Coffino P. Regulation of cellular polyamines by antizyme. Nat Rev Mol Cell Biol 2001;2:188-194.
14. Davidson NE, Hahm HA, McCloskey DE, Woster PM, Casero RA, Jr. Clinical aspects of cell death in breast cancer: The polyamine pathway as a new target for treatment. Endocrinol Relat Cancer 1999;6:69-73.
15. Feng Y, Piletz JE, Leblanc MH. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 2002;52:606-611.
16. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996; 316(Pt 1):247-249.
17. Gonzalez C, Regunathan S, Reis DJ, Estrada C. Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery. Br J Pharmacol 1996;119:677-684.
18. Greenberg S, Finkelstein A, Gurevich J, et al. The effect of agmatine on ischemic and nonischemic isolated rat heart. J Cardiovasc Pharmacol Ther 1999;4:151-158.
19. Gründemann D, Hahne C, Berkels R, Schömig E. Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J Pharmacol Exp Ther 2003;304:810-817.
20. Gründemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1999;1:349-351.
21. Halaris A, Zhu H, Feng Y, Piletz JE. Plasma agmatine and platelet imidazoline receptors in depression. Am NY Acad Sci 1999;881:445-451.
22. Igarashi K, Kashiwagi K. Polyamines: Mysterious modulators of cellular functions. Biochem Biophys Res Commun 2000;271:559-564.
23. Ishikawa T, Misonou T, Ikeno M, Sato K, Sakamaki T. N-ω -hydroxyagmatine: A novel substance causing endothelium-dependent vasorelaxation. Biochem Biophys Res Commun 1995;214:145-151.
24. Iyer RK, Kim HK, Tsoa RW, Grody WW, Cederbaum SD. Cloning and characterization of human agmatinase. Mol Gen Metah 2002;75:209-218.
25. Karadag HC, Ulugol A, Tamer M, Ipci Y, Dokmeci I. Systemic agmatine attenuates tactile allodynia in two experimental neuropathic pain models in rats. Neurosci Lett 2003;339:88-90.
26. Kolesnikov Y, Jain S, Pasternak GW. Modulation of opioid analgesia by agmatine. Eur J Pharmacol 1996; 296:17-22.
27. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: An endogenous clonidine-displacing substance in the brain. Science 1994;263:966-969.
28. Li Q, He RR. Hemodynamic effects of agmatine in Dahl salt-sensitive hypertensive and Dahl salt-resistant rats. Sheng Li Xue Bao 2001;53:355-360.
29. Li XT, He RR, Liu S, et al. Electrophysiological effects of agmatine on human atrial fibers. Life Sci 2000;66:2351-2356.
30. Lortie MJ, Novotny WF, Peterson OW, et al. Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat. J Clin Invest 1996;97:413-420.
31. Medina MA, Urdiales JL, Rodriguez-Caso C, Ramirez FJ, Sanchez-Jimenez F. Biogenic amines and polyamines: Similar biochemistry for different physiological missions and biomedical applications. Crit Rev Biochem Mol Biol 2003;38:23-59.
32. Mistry SK, Burwell TJ, Chambers RM, et al. Cloning of human agmatinase. An alternate path for polyamine synthesis induced in liver by hepatitis B virus. Am J Physiol Gastrointest Liver Physiol 2002;282:G375-381.
33. Molderings GJ, Burian M, Homann J, Nilius M, Gothert M. Potential relevance of agmatine as a virulence factor of Helicobacter pylori. Dig Dis Sci 1999;44:2397-2404.
34. Molderings GJ, Burian M, Menzel S, et al. Imidazoline recognition sites and stomach function. Ann NY Acad Sci 1999;881:332-343.
35. Molderings GJ, Gothert M. Imidazoline binding sites and receptors in cardiovascular tissue. Gen Pharmacol 1999;32:17-22.
36. Morrissey J, McCracken R, Ishidoya S, Klahr S. Partial cloning and characterization of an arginine decarboxylase in the kidney. Kidney Int 1995;47:1458-1461.
37. Morrissey JJ, Klahr S. Agmatine activation of nitric oxide synthase in endothelial cells. Proc Assoc Am Physicians 1997;109:51-57.
38. Olmos G, DeGregorio-Rocasolano N, Paz Regalado M, et al. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol 1999;127:1317-1326.
39. Onal A, Delen Y, Ulker S, Soykan N. Agmatine attenuates neuropathic pain in rats: Possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum. Life Sci 2003;73:413-428.
40. Otake K, Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ, Regional localization of agmatine in the rat brain: An immunocytochemical study. Brain Res 1998;787:1-14.
41. Ozyazgan S, Bicakci B, Ozaydin A, Denizbasi A, Unluer EE, Akkan AG. The effect of agmatine on the vascular reactivity in streptozotocin-diabetic rats. Pharmacol Res 2003;48:133-138.
42. Pegg AE, Feith DJ, Fong LY, Coleman CS, O'Brien TG, Shantz LM. Transgenic mouse models for studies of the role of polyamines in normal, hypertrophic and neoplastic growth. Biochem Soc Trans 2003;31:356-360.
43. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982;243:C212-221.
44. Penner SB, Smyth DD. Natriuresis following central and peripheral administration of agmatine in the rat. Pharmacology 1996;53:160-169.
45. 1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. J Psychiatr Res 1996;30:169-184.
46. Piletz JE, Ordway GA, Rajkowska G, et al. Differential expression of alpha(2)-adrenoceptor vs. imidazoline binding sites in postmortem orbitofrontal cortex and amygdala of depressed subjects. J Psychiatr Res 2003; 37:399-409.
47. Pineda J, Ruiz-Ortega JA, Martin-Ruiz R, Ugedo L. Agmatine does not have activity at alpha2-adrenoceptors which modulate the firing rate of locus coeruleus neurones: An electrophysiological study in rat. Neurosci Lett 1996;219:103-106.
48. Pinthong D, Wright IK, Hanmer C, et al. Agmatine recognizes alpha2-adrenoceptor binding sites but neither activates nor inhibits alpha2-adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 1995;351:10-16.
49. Raasch W, Chun KRJ, Dendorfer A, Dominiak P. Positive inotropic effects of imidazoline derivatives are not mediated via imidazoline binding sites but alpha1-adrenergic receptors. Jpn J Pharmacol 2000;84:1-6.
50. Raasch W, Regunathan S, Li G, Reis DJ. Agmatine is widely and unequally distributed in rat organs. Ann NY Acad Sci 1995;763:330-334.
51. Raasch W, Regunathan S, Li G, Reis DJ. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci 1995;56:2319-2330.
52. Raasch W, Schafer U, Chun J, Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br J Pharmacol 2001;133:755-780.
53. Regunathan S, Feinstein DL, Reis DJ. Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved? Ann NY Acad Sci 1999;881:410-419.
54. Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 1996;36:511-544.
55. Regunathan S, Youngson C, Raasch W, Wang H, Reis DJ. Imidazoline receptors and agmatine in blood vessels: A novel system inhibiting vascular smooth muscle proliferation. J Pharmacol Exp Ther 1996;276: 1272-1282.
56. Reis DJ, Regunathan S. Agmatine: A novel neurotransmitter? Adv Pharmacol 1998;42:645-649.
57. Reis DJ, Regunathan S. Agmatine: An endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann NY Acad Sci 1999;881:65-80.
58. Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 2000;21: 187-193.
59. Sastre M, Galea E, Feinstein D, Reis DJ, Regunathan S. Metabolism of agmatine in macrophages: Modulation by lipopolysaccharide and inhibitory cytokines. Biochem J 1998;330(Pt 3):1405-149.
60. Sastre M, Regunathan S, Galea E, Reis DJ. Agmatinase activity in rat brain: A metabolic pathway for the degradation of agmatine. J Neurochem 1996;67:1761-1765.
61. Sastre M, Regunathan S, Reis DJ. Uptake of agmatine into rat brain synaptosomes: Possible role of cation channels. J Neurochem 1997;69:2421-2426.
62. Satriano J, Matsufuji S, Murakami Y, et al. Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels. J Biol Chem 1998;273:15313-15316.
63. Satriano J, Schwartz D, Ishizuka S, et al. Suppression of inducible nitric oxide generation by agmatine aldehyde: Beneficial effects in sepsis. J Cell Physiol 2001;188:313-320.
64. Schafer U, Raasch W, Qadri F, Chun J, Dominiak P. Effects of agmatine on the cardiovascular system of spontaneously hypertensive rats. Ann NY Acad Sci 1999;881:97-101.
65. Schwartz D, Peterson OW, Mendonca M, Satriano J, Lortie M, Blantz RC. Agmatine affects glomerular filtration via a nitric oxide synthase-dependent mechanism. Am J Physiol 1997;272:F597-601.
66. Sener A, Lebrun P, Blachier F, Malaisse WJ. Stimulus-secretion coupling of arginine-induced insulin release. Insulinotropic action of agmatine. Biochem Pharmacol 1989;38:327-330.
67. 1-imidazoline receptor-selective compounds mediate natriuresis in the rat. J Cardiovasc Pharmacol 1995;26(Suppl 2):S63-67.
68. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984;53:749-790.
69. 2-imidazoline binding sites on monoamine oxidases. J Biol Chem 1995;270:9856-9861.
70. Urdiales JL, Medina MA, Sanchez-Jimenez F. Polyamine metabolism revisited. Eur J Gastroenterol Hepatol 2001;13:1015-1019.
71. Vargiu C, Cabella C, Belliardo S, Cravanzola C, Grillo MA, Colombatto S. Agmatine modulates polyamine content in hepatocytes by inducing spermidine/spermine acetyltransferase. Eur J Biochem 1999;259: 933-938.
72. Wu G, Morris SM, Jr. Arginine metabolism: Nitric oxide and beyond. Biochem J 1998;336(Pt 1):1-17.
73. Yang XC, Reis DJ. Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther 1999;288:544-549.
74. Zhang M, Pickart CM, Coffino P. Determinants of proteasome recognition of omithine decarboxylase, a ubiquitin-independent substrate. EMBO J 2003;22:1488-1496.